Infinimmune
Updated: August 16, 2026
CEO - Wyatt McDonnell
Country: USA | Funding: $87M (+)
Founded: 2022
Website: https://www.infinimmune.com
Infinimmune develops human-derived antibody medicines using B-cell sequencing, computational modeling, and antibody engineering technology. The startup is backed by Regeneron that is financing the development of a potential competitor to its inflammation blockbuster Dupixent for treating eczema, asthma, and COPD.
Founded: 2022
Website: https://www.infinimmune.com
Infinimmune develops human-derived antibody medicines using B-cell sequencing, computational modeling, and antibody engineering technology. The startup is backed by Regeneron that is financing the development of a potential competitor to its inflammation blockbuster Dupixent for treating eczema, asthma, and COPD.
